Novavax (NVAX) PT Raised to $61 at B.Riley/FBR, Following Acquisition Of Praha Vaccines
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $9.70 -2.9%
Rating Summary:
10 Buy, 3 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
10 Buy, 3 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
B.Riley/FBR analyst Mayank Mamtani raised the price target on Novavax (NASDAQ: NVAX) to $61.00 (from $53.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Pinnacle Financial Partners (PNFP) PT Raised to $115 at DA Davidson
- Tango Therapeutics Inc. (TNGX) PT Raised to $45 at Wedbush
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
